Form 4: Syndax Pharmaceuticals CFO Keith A. Goldan Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Keith A. Goldan, CFO of Syndax Pharmaceuticals, sold 3,777 shares of common stock on February 10, 2025, to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On February 10, 2025, Keith A. Goldan, the Chief Financial Officer of Syndax Pharmaceuticals Inc., sold 3,777 shares of the company's common stock.
- The sale was executed at a price of $15.504 per share.
- The transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
- Following the transaction, Goldan directly owns 90,746 shares of Syndax Pharmaceuticals Inc.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine sale of shares to cover tax obligations, which is a common practice among executives.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and actions regarding their company's stock.
Key Dates
| Date | Description |
|---|---|
| 02/10/2025 | Date of the transaction: Keith A. Goldan sold shares of Syndax Pharmaceuticals Inc. |
| 02/12/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.